News
ARVN
7.31
+0.14%
0.01
Weekly Report: what happened at ARVN last week (1012-1016)?
Weekly Report · 10/19 09:17
Big Pharma Is Pouring Billions Into a New Class of 'Protein Degrader' Drugs
The Wall Street Journal · 10/15 09:30
Weekly Report: what happened at ARVN last week (1005-1009)?
Weekly Report · 10/12 09:18
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch Health Companies (BHC), Arvinas Holding Company (ARVN) and Ovid Therapeutics (OVID)
TipRanks · 10/08 12:40
Analysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF), Arvinas Holding Company (ARVN) and Halozyme (HALO)
TipRanks · 10/08 09:20
Arvinas Fell While It Turned A Profit
Simply Wall St · 10/08 07:30
Arvinas' ARV-102 Shows Biomarker Changes In Parkinson's Phase 1 Trial
NASDAQ · 10/07 11:37
Arvinas presents data from clinical trial of ARV-102
TipRanks · 10/07 11:05
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
Barchart · 10/07 06:00
Weekly Report: what happened at ARVN last week (0928-1002)?
Weekly Report · 10/05 09:18
Arvinas To Present Biomarker Data From Phase 1 Clinical Trial Of ARV-102 In Participants With Parkinson’s Disease At 2026 International Congress Of Parkinson’s Disease And Movement Disorders
Benzinga · 10/01 20:02
Press Release: Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Dow Jones · 09/29 20:01
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 09/29 15:01
Arvinas Advances ARV-6723 Into Phase 1/2 Trial In Advanced Solid Tumors
NASDAQ · 09/28 11:29
Arvinas announces first patient dosed in Phase 1/2 trial of ARV-6723
TipRanks · 09/28 11:11
Weekly Report: what happened at ARVN last week (0921-0925)?
Weekly Report · 09/28 09:17
Arvinas Q2 2026 Earnings Call Transcript
Benzinga · 09/25 11:25
Weekly Report: what happened at ARVN last week (0914-0918)?
Weekly Report · 09/21 09:17
Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains?
NASDAQ · 09/18 16:31
Analysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (OLMA) and Arvinas Holding Company (ARVN)
TipRanks · 09/14 12:20
More
Webull provides a variety of real-time ARVN stock news. You can receive the latest news about Arvinas through multiple platforms. This information may help you make smarter investment decisions.
About ARVN
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393, ARV-102, ARV-80, and ARV-027. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC to degrade BCL6, a transcriptional repressor and a regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.